Question

In: Accounting

Camden Biotechnology began operations in September 2016. The following selected transactions relate to liabilities of the...

Camden Biotechnology began operations in September 2016. The following selected transactions relate to liabilities of the company for September 2016 through March 2017. Camden’s fiscal year ends on December 31. Its financial statements are issued in April.

2016
a.

On September 5, opened checking accounts at Second Commercial Bank and negotiated a short-term line of credit of up to $29,000,000 at the bank’s prime rate (9.5% at the time). The company will pay no commitment fees.

b.

On October 1, borrowed $26 million cash from Second Commercial Bank under the line of credit and issued a five-month promissory note. Interest at the prime rate of 9% was payable at maturity. Management planned to issue 10-year bonds in February to repay the note.

c.

Received $3,900 of refundable deposits in December for reusable containers used to transport and store chemical-based products.

d.

For the September–December period, sales on account totaled $4,410,000. The state sales tax rate is 3% and the local sales tax rate is 3%. (This is a summary journal entry for the many individual sales transactions for the period.)

e. Recorded the adjusting entry for accrued interest.

2017
f.

In February, issued $25 million of 10-year bonds at face value and paid the bank loan on the March 1 due date.

g.

Half of the storage containers covered by refundable deposits were returned in March. The remaining containers are expected to be returned during the next six months.

Required:
1.

Prepare the appropriate journal entries for 2016 and 2017 transactions. (If no entry is required for a transaction/event, select "No journal entry required" in the first account field. Enter your answers in whole dollars.)

1

On September 5, opened checking accounts at Second Commercial Bank and negotiated a short-term line of credit of up to $29,000,000 at the bank’s prime rate (9.5% at the time). The company will pay no commitment fees.

2

On October 1, borrowed $26 million cash and issued a five-month promissory note. Interest at the prime rate of 9% was payable at maturity. Management planned to issue 10-year bonds in February to repay the note.

3

Received $3,900 of refundable deposits in December for reusable containers used to transport and store chemical-based products.

4

For the September–December period, sales on account totaled $4,410,000. The state sales tax rate is 3% and the local sales tax rate is 3%.

5

Recorded the adjusting entry for accrued interest.

6

In February, issued $25.0 million of 10-year bonds.

7

Record the payment of the bank loan due on March 1.

8

Half of the storage containers covered by refundable deposits were returned in March. The remaining containers are expected to be returned during the next six months.

Prepare the current and long-term liability sections of the December 31, 2016, balance sheet. Trade accounts payable on that date were $324,000.

Balance Sheet (partial)
At December 31, 2016
Current liabilities:
Total current liabilities $0
Long-term liabilities:

Solutions

Expert Solution

Journal Entries for 2016 and 2017 transactions

Date Particulars Dr. Amount Cr. Amount
05.09.2016 No Journal Entry Required
01.10.2016 Cash $26,000,000
Notes Payable $26,000,000
(To record five month bank loan)
31.12.2016 Cash $3,900
Refundable Deposit $3,900
(To record receipt of refundable deposit)
31.12.2016 Account Receivable $4,674,600
Sales Revnue $4,410,000
State Sales Tax @ 3% $132,300
Local Sales Tax @ 3% $132,300
(To recoed sales on account)
31.12.2016 Interest Expense $598,000
Interest Payable $598,000
$26000000 * 9% * (92 days in Oct-Dec / 360 days in year)
(To record accrued interest on note at year end)
28.02.2017 Cash $25,000,000
Bonds Payable $25,000,000
(To record 10 year bonds)
01.03.2017 Notes Payable $26,000,000
Interest Payable $598,000
Interest Expense $383,500
$26000000 * 9% * (59 days in Oct-Dec / 360 days in year)
Cash $26,981,500
(To record principal and interest paid on bank loan)
31.03.2017 Refundable Deposit $1,950
Cash $1,950
(To record return of 50% of refundable deposit)

Current and Long-term Liability Sections of the Balance Sheet as at 31.12.2016

Balance Sheet (Partial)
As At December 31, 2016
Particulars Amount
Current Liabilities:
Notes Payable $26,000,000
Refundable Deposit $3,900
Interest Payable $598,000
Trade Accounts Payable $324,000
Total Current Liabilities $26,925,900
Long-term Liabilities $0

Related Solutions

Camden Biotechnology began operations in September 2021. The following selected transactions relate to liabilities of the...
Camden Biotechnology began operations in September 2021. The following selected transactions relate to liabilities of the company for September 2021 through March 2022. Camden’s fiscal year ends on December 31. Its financial statements are issued in April. 2021 On September 5, opened checking accounts at Second Commercial Bank and negotiated a short-term line of credit of up to $25,000,000 at the bank's prime rate (9.5% at the time). The company will pay no commitment fees. On October 1, borrowed $22...
Camden Biotechnology began operations in September 2018. The following selected transactions relate to liabilities of the...
Camden Biotechnology began operations in September 2018. The following selected transactions relate to liabilities of the company for September 2018 through March 2019. Camden’s fiscal year ends on December 31. Its financial statements are issued in April. 2018 On September 5, opened checking accounts at Second Commercial Bank and negotiated a short-term line of credit of up to $15,000,000 at the bank's prime rate (10.5% at the time). The company will pay no commitment fees. On October 1, borrowed $12...
Camden Biotechnology began operations in September 2018. The following selected transactions relate to liabilities of the...
Camden Biotechnology began operations in September 2018. The following selected transactions relate to liabilities of the company for September 2018 through March 2019. Camden’s fiscal year ends on December 31. Its financial statements are issued in April. 2018 On September 5, opened checking accounts at Second Commercial Bank and negotiated a short-term line of credit of up to $23,000,000 at the bank’s prime rate (9.5% at the time). The company will pay no commitment fees. On October 1, borrowed $20...
Camden Biotechnology began operations in September 2018. The following selected transactions relate to liabilities of the...
Camden Biotechnology began operations in September 2018. The following selected transactions relate to liabilities of the company for September 2018 through March 2019. Camden’s fiscal year ends on December 31. Its financial statements are issued in April. 2018 On September 5, opened checking accounts at Second Commercial Bank and negotiated a short-term line of credit of up to $8,000,000 at the bank’s prime rate (9.5% at the time). The company will pay no commitment fees. On October 1, borrowed $5...
Camden Biotechnology began operations in September 2018. The following selected transactions relate to liabilities of the...
Camden Biotechnology began operations in September 2018. The following selected transactions relate to liabilities of the company for September 2018 through March 2019. Camden’s fiscal year ends on December 31. Its financial statements are issued in April. 2018 On September 5, opened checking accounts at Second Commercial Bank and negotiated a short-term line of credit of up to $19,000,000 at the bank’s prime rate (12.5% at the time). The company will pay no commitment fees. On October 1, borrowed $16...
Camden Biotechnology began operations in September 2018. The following selected transactions relate to liabilities of the...
Camden Biotechnology began operations in September 2018. The following selected transactions relate to liabilities of the company for September 2018 through March 2019. Camden’s fiscal year ends on December 31. Its financial statements are issued in April. 2018 On September 5, opened checking accounts at Second Commercial Bank and negotiated a short-term line of credit of up to $19,000,000 at the bank’s prime rate (12.5% at the time). The company will pay no commitment fees. On October 1, borrowed $16...
Camden Biotechnology began operations in September 2018. The following selected transactions relate to liabilities of the...
Camden Biotechnology began operations in September 2018. The following selected transactions relate to liabilities of the company for September 2018 through March 2019. Camden’s fiscal year ends on December 31. Its financial statements are issued in April. 2018 On September 5, opened checking accounts at Second Commercial Bank and negotiated a short-term line of credit of up to $19,000,000 at the bank’s prime rate (12.5% at the time). The company will pay no commitment fees. On October 1, borrowed $16...
Camden Biotechnology began operations in September 2018. The following selected transactions relate to liabilities of the...
Camden Biotechnology began operations in September 2018. The following selected transactions relate to liabilities of the company for September 2018 through March 2019. Camden’s fiscal year ends on December 31. Its financial statements are issued in April. 2018 On September 5, opened checking accounts at Second Commercial Bank and negotiated a short-term line of credit of up to $25,000,000 at the bank’s prime rate (9.5% at the time). The company will pay no commitment fees. On October 1, borrowed $22...
The following selected transactions relate to contingencies of Eastern Products Inc., which began operations in July...
The following selected transactions relate to contingencies of Eastern Products Inc., which began operations in July 2021. Eastern's fiscal year ends on December 31. Financial statements are published in April 2022. No customer accounts have been shown to be uncollectible as yet, but Eastern estimates that 3% of credit sales will eventually prove uncollectible. Sales were $300 million (all credit) for 2021. Eastern offers a one-year warranty against manufacturer's defects for all its products. Industry experience indicates that warranty costs...
The following selected transactions relate to contingencies of Classical Tool Makers, Inc., which began operations in...
The following selected transactions relate to contingencies of Classical Tool Makers, Inc., which began operations in July 2021. Classical’s fiscal year ends on December 31. Financial statements are issued in April 2022. Classical’s products carry a one-year warranty against manufacturer’s defects. Based on previous experience, warranty costs are expected to approximate 3% of sales. Sales were $2.3 million (all credit) for 2021. Actual warranty expenditures were $20,100 and were recorded as warranty expense when incurred. Although no customer accounts have...
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT